Alaproclate

Jump to: navigation, search
Alaproclate
Alaproclate structure.png
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC13H18ClNO2
Molar mass255.740 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Alaproclate

Articles

Most recent articles on Alaproclate

Most cited articles on Alaproclate

Review articles on Alaproclate

Articles on Alaproclate in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Alaproclate

Images of Alaproclate

Photos of Alaproclate

Podcasts & MP3s on Alaproclate

Videos on Alaproclate

Evidence Based Medicine

Cochrane Collaboration on Alaproclate

Bandolier on Alaproclate

TRIP on Alaproclate

Clinical Trials

Ongoing Trials on Alaproclate at Clinical Trials.gov

Trial results on Alaproclate

Clinical Trials on Alaproclate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alaproclate

NICE Guidance on Alaproclate

NHS PRODIGY Guidance

FDA on Alaproclate

CDC on Alaproclate

Books

Books on Alaproclate

News

Alaproclate in the news

Be alerted to news on Alaproclate

News trends on Alaproclate

Commentary

Blogs on Alaproclate

Definitions

Definitions of Alaproclate

Patient Resources / Community

Patient resources on Alaproclate

Discussion groups on Alaproclate

Patient Handouts on Alaproclate

Directions to Hospitals Treating Alaproclate

Risk calculators and risk factors for Alaproclate

Healthcare Provider Resources

Symptoms of Alaproclate

Causes & Risk Factors for Alaproclate

Diagnostic studies for Alaproclate

Treatment of Alaproclate

Continuing Medical Education (CME)

CME Programs on Alaproclate

International

Alaproclate en Espanol

Alaproclate en Francais

Business

Alaproclate in the Marketplace

Patents on Alaproclate

Experimental / Informatics

List of terms related to Alaproclate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Alaproclate (GEA-654) is a psychoactive drug and research chemical that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. Some studies have found that it acts as a noncompetitive NMDA antagonist, but does not have discriminative stimulus properties similar to phencyclidine.[1][2]

Synthesis

Alaproclate synthesis:[3]

See also

References

  1. Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE (December 1994). "Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow". The Journal of Pharmacology and Experimental Therapeutics. 271 (3): 1314–9. PMID 7996440. (Subscription required (help)).
  2. Nicholson KL, Balster RL (November 2003). "Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats". Psychopharmacology (Berlin). 170 (2): 215–24. doi:10.1007/s00213-003-1527-6. PMID 12851738. (Subscription required (help)).
  3. Template:Cite doi

Linked-in.jpg